How is Pfizer Tackling the “Blockbuster Drug Drought” in the Post-Pandemic Era?

Life Science

Insider Cashes Out, Hedge Fund Piles In: The Two Faces of Olema After a 300% Rally

Life Science

Logos Bought, Alpine Sold: Is Immunovant a Buy or a Red Flag?

Life Science

Three Berkshire-Related Stocks Worth Watching: Chevron, Domino’s Pizza, and DaVita

Consumer Goods, Life Science

Top Five Cloud Computing ETF Recommendations for 2026

Life Science

Novo Nordisk Partners with Hims & Hers: Can Turning a Foe into a Friend Reverse the Downturn?

Life Science

Why Microsoft Is a Safe Bet in the AI Era, Despite Moderate Stock Gains

Life Science, Technology

Is GeneDx, the Stock Cathie Wood Bought for 7 Straight Days, Actually Cheap?

Life Science

Seeking a Bottom in Choppy Markets? Two Long-Term Picks with “Anti-Fragile” Qualities

Life Science, Technology

The Obesity Drug War Goes Oral: Why Eli Lilly’s Orforglipron Could Steal the Spotlight from Novo

Life Science

Can Viking Therapeutics Capitalize on Weight Loss Drugs for a Comeback?

Life Science

This Stock Soared 1600% in a Year! Billionaire Cohen Had Already Positioned Himself

Life Science

Intuitive Surgical and DexCom: Why the Dips Are Buying Opportunities

Life Science

A Tenfold Increase in a Decade? What Makes This Small Biotech Company So Special

Life Science

Novo Nordisk’s Price Cuts and R&D Progress Go Hand in Hand, GLP-1 Drug Prices Reduced by Up to 50%

Life Science